Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Anti-Obesity Therapeutics Market 2018, Forecast to 2023

  • receipt Report ID : 138327
  • calendar_today Published On: Jan, 2019
  • file_copy Pages: 128
  • list Pharmaceuticals and Healthcare

Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.

Scope of the Report:

This report focuses on the Anti-Obesity Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.

The worldwide market for Anti-Obesity Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers

Bristol-Myers Squibb

Eisai Company

FlaxoSithKline plc.

Novo Nordisk

Alizyme

BoehringerIngelheim GmbH

Pfizer

Takeda Pharmaceutical

Rhythm Pharmaceuticals

Shionogi USA

Vivus

Zafgen

Norgine Pharmaceuticals Ltd.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Centrally Acting Anti-obesity Drugs

Peripherally Acting Anti-obesity Drugs

Market Segment by Applications, can be divided into

Hospital Use

Clinic Use

Household

Other

There are 15 Chapters to deeply display the global Anti-Obesity Therapeutics market.

Chapter 1, to describe Anti-Obesity Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Anti-Obesity Therapeutics, with sales, revenue, and price of Anti-Obesity Therapeutics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Obesity Therapeutics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Anti-Obesity Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Anti-Obesity Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Anti-Obesity Therapeutics Introduction

1.2 Market Analysis by Type

1.2.1 Centrally Acting Anti-obesity Drugs

1.2.2 Peripherally Acting Anti-obesity Drugs

1.3 Market Analysis by Applications

1.3.1 Hospital Use

1.3.2 Clinic Use

1.3.3 Household

1.3.4 Other

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Bristol-Myers Squibb

2.1.1 Business Overview

2.1.1.1 Bristol-Myers Squibb Description

2.1.1.2 Bristol-Myers Squibb Headquarter, Main Business and Finance Overview

2.1.2 Bristol-Myers Squibb Anti-Obesity Therapeutics Product Introduction

2.1.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.1.2.2 Anti-Obesity Therapeutics Product Information

2.1.3 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.1 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.2 Global Bristol-Myers Squibb Anti-Obesity Therapeutics Market Share in 2017

2.2 Eisai Company

2.2.1 Business Overview

2.2.1.1 Eisai Company Description

2.2.1.2 Eisai Company Headquarter, Main Business and Finance Overview

2.2.2 Eisai Company Anti-Obesity Therapeutics Product Introduction

2.2.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.2.2.2 Anti-Obesity Therapeutics Product Information

2.2.3 Eisai Company Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.1 Eisai Company Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.2 Global Eisai Company Anti-Obesity Therapeutics Market Share in 2017

2.3 FlaxoSithKline plc.

2.3.1 Business Overview

2.3.1.1 FlaxoSithKline plc. Description

2.3.1.2 FlaxoSithKline plc. Headquarter, Main Business and Finance Overview

2.3.2 FlaxoSithKline plc. Anti-Obesity Therapeutics Product Introduction

2.3.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.3.2.2 Anti-Obesity Therapeutics Product Information

2.3.3 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.1 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.2 Global FlaxoSithKline plc. Anti-Obesity Therapeutics Market Share in 2017

2.4 Novo Nordisk

2.4.1 Business Overview

2.4.1.1 Novo Nordisk Description

2.4.1.2 Novo Nordisk Headquarter, Main Business and Finance Overview

2.4.2 Novo Nordisk Anti-Obesity Therapeutics Product Introduction

2.4.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.4.2.2 Anti-Obesity Therapeutics Product Information

2.4.3 Novo Nordisk Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4.3.1 Novo Nordisk Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4.3.2 Global Novo Nordisk Anti-Obesity Therapeutics Market Share in 2017

2.5 Alizyme

2.5.1 Business Overview

2.5.1.1 Alizyme Description

2.5.1.2 Alizyme Headquarter, Main Business and Finance Overview

2.5.2 Alizyme Anti-Obesity Therapeutics Product Introduction

2.5.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.5.2.2 Anti-Obesity Therapeutics Product Information

2.5.3 Alizyme Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5.3.1 Alizyme Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5.3.2 Global Alizyme Anti-Obesity Therapeutics Market Share in 2017

2.6 BoehringerIngelheim GmbH

2.6.1 Business Overview

2.6.1.1 BoehringerIngelheim GmbH Description

2.6.1.2 BoehringerIngelheim GmbH Headquarter, Main Business and Finance Overview

2.6.2 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Introduction

2.6.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.6.2.2 Anti-Obesity Therapeutics Product Information

2.6.3 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6.3.1 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6.3.2 Global BoehringerIngelheim GmbH Anti-Obesity Therapeutics Market Share in 2017

2.7 Pfizer

2.7.1 Business Overview

2.7.1.1 Pfizer Description

2.7.1.2 Pfizer Headquarter, Main Business and Finance Overview

2.7.2 Pfizer Anti-Obesity Therapeutics Product Introduction

2.7.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.7.2.2 Anti-Obesity Therapeutics Product Information

2.7.3 Pfizer Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7.3.1 Pfizer Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7.3.2 Global Pfizer Anti-Obesity Therapeutics Market Share in 2017

2.8 Takeda Pharmaceutical

2.8.1 Business Overview

2.8.1.1 Takeda Pharmaceutical Description

2.8.1.2 Takeda Pharmaceutical Headquarter, Main Business and Finance Overview

2.8.2 Takeda Pharmaceutical Anti-Obesity Therapeutics Product Introduction

2.8.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.8.2.2 Anti-Obesity Therapeutics Product Information

2.8.3 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8.3.1 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8.3.2 Global Takeda Pharmaceutical Anti-Obesity Therapeutics Market Share in 2017

2.9 Rhythm Pharmaceuticals

2.9.1 Business Overview

2.9.1.1 Rhythm Pharmaceuticals Description

2.9.1.2 Rhythm Pharmaceuticals Headquarter, Main Business and Finance Overview

2.9.2 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Introduction

2.9.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.9.2.2 Anti-Obesity Therapeutics Product Information

2.9.3 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9.3.1 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9.3.2 Global Rhythm Pharmaceuticals Anti-Obesity Therapeutics Market Share in 2017

2.10 Shionogi USA

2.10.1 Business Overview

2.10.1.1 Shionogi USA Description

2.10.1.2 Shionogi USA Headquarter, Main Business and Finance Overview

2.10.2 Shionogi USA Anti-Obesity Therapeutics Product Introduction

2.10.2.1 Anti-Obesity Therapeutics Production Bases, Sales Regions and Major Competitors

2.10.2.2 Anti-Obesity Therapeutics Product Information

2.10.3 Shionogi USA Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10.3.1 Shionogi USA Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10.3.2 Global Shionogi USA Anti-Obesity Therapeutics Market Share in 2017

2.11 Vivus

2.11.1 Business Overview

2.11.2 Vivus Anti-Obesity Therapeutics Product Introduction

2.11.3 Vivus Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.12 Zafgen

2.12.1 Business Overview

2.12.2 Zafgen Anti-Obesity Therapeutics Product Introduction

2.12.3 Zafgen Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.13 Norgine Pharmaceuticals Ltd.

2.13.1 Business Overview

2.13.2 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Introduction

2.13.3 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Anti-Obesity Therapeutics Market Competition, by Manufacturer

3.1 Global Anti-Obesity Therapeutics Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

3.3 Global Anti-Obesity Therapeutics Price by Manufacturer (2016-2017)

3.4 Market Concentration Rate

3.4.1 Top 3 Anti-Obesity Therapeutics Manufacturer Market Share in 2017

3.4.2 Top 5 Anti-Obesity Therapeutics Manufacturer Market Share in 2017

3.5 Market Competition Trend

4 Global Anti-Obesity Therapeutics Market Analysis by Regions

4.1 Global Anti-Obesity Therapeutics Sales, Revenue and Market Share by Regions

4.1.1 Global Anti-Obesity Therapeutics Sales by Regions (2013-2018)

4.1.2 Global Anti-Obesity Therapeutics Revenue by Regions (2013-2018)

4.2 North America Anti-Obesity Therapeutics Sales, Revenue and Growth Rate (2013-2018)

4.3 Europe Anti-Obesity Therapeutics Sales, Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Anti-Obesity Therapeutics Sales, Revenue and Growth Rate (2013-2018)

4.5 South America Anti-Obesity Therapeutics Sales, Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Anti-Obesity Therapeutics Sales, Revenue and Growth Rate (2013-2018)

5 North America Anti-Obesity Therapeutics by Countries, Type, Application and Manufacturers

5.1 North America Anti-Obesity Therapeutics Sales, Revenue and Market Share by Countries

5.1.1 North America Anti-Obesity Therapeutics Sales by Countries (2013-2018)

5.1.2 North America Anti-Obesity Therapeutics Revenue by Countries (2013-2018)

5.1.3 United States Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

5.1.4 Canada Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

5.1.5 Mexico Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

5.2 North America Anti-Obesity Therapeutics Sales and Revenue (Value) by Manufacturers (2016-2017)

5.2.1 North America Anti-Obesity Therapeutics Sales by Manufacturers (2016-2017)

5.2.2 North America Anti-Obesity Therapeutics Revenue by Manufacturers (2016-2017)

5.3 North America Anti-Obesity Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

5.3.1 North America Anti-Obesity Therapeutics Sales and Sales Share by Type (2013-2018)

5.3.2 North America Anti-Obesity Therapeutics Revenue and Revenue Share by Type (2013-2018)

5.4 North America Anti-Obesity Therapeutics Sales, Revenue and Market Share by Application (2013-2018)

5.4.1 North America Anti-Obesity Therapeutics Sales and Sales Share by Application (2013-2018)

5.4.2 North America Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2013-2018)

6 Europe Anti-Obesity Therapeutics by Countries, Type, Application and Manufacturers

6.1 Europe Anti-Obesity Therapeutics Sales, Revenue and Market Share by Countries

6.1.1 Europe Anti-Obesity Therapeutics Sales by Countries (2013-2018)

6.1.2 Europe Anti-Obesity Therapeutics Revenue by Countries (2013-2018)

6.1.3 Germany Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

6.1.4 UK Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

6.1.5 France Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

6.1.6 Russia Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

6.1.7 Italy Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

6.2 Europe Anti-Obesity Therapeutics Sales and Revenue (Value) by Manufacturers (2016-2017)

6.2.1 Europe Anti-Obesity Therapeutics Sales by Manufacturers (2016-2017)

6.2.2 Europe Anti-Obesity Therapeutics Revenue by Manufacturers (2016-2017)

6.3 Europe Anti-Obesity Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

6.3.1 Europe Anti-Obesity Therapeutics Sales and Sales Share by Type (2013-2018)

6.3.2 Europe Anti-Obesity Therapeutics Revenue and Revenue Share by Type (2013-2018)

6.4 Europe Anti-Obesity Therapeutics Sales, Revenue and Market Share by Application (2013-2018)

6.4.1 Europe Anti-Obesity Therapeutics Sales and Sales Share by Application (2013-2018)

6.4.2 Europe Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2013-2018)

7 Asia-Pacific Anti-Obesity Therapeutics by Countries, Type, Application and Manufacturers

7.1 Asia-Pacific Anti-Obesity Therapeutics Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Anti-Obesity Therapeutics Sales by Countries (2013-2018)

7.1.2 Asia-Pacific Anti-Obesity Therapeutics Revenue by Countries (2013-2018)

7.1.3 China Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

7.1.4 Japan Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

7.1.5 Korea Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

7.1.6 India Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

7.1.7 Southeast Asia Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

7.2 Asia-Pacific Anti-Obesity Therapeutics Sales and Revenue (Value) by Manufacturers (2016-2017)

7.2.1 Asia-Pacific Anti-Obesity Therapeutics Sales by Manufacturers (2016-2017)

7.2.2 Asia-Pacific Anti-Obesity Therapeutics Revenue by Manufacturers (2016-2017)

7.3 Asia-Pacific Anti-Obesity Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

7.3.1 Asia-Pacific Anti-Obesity Therapeutics Sales and Sales Share by Type (2013-2018)

7.3.2 Asia-Pacific Anti-Obesity Therapeutics Revenue and Revenue Share by Type (2013-2018)

7.4 Asia-Pacific Anti-Obesity Therapeutics Sales, Revenue and Market Share by Application (2013-2018)

7.4.1 Asia-Pacific Anti-Obesity Therapeutics Sales and Sales Share by Application (2013-2018)

7.4.2 Asia-Pacific Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2013-2018)

8 South America Anti-Obesity Therapeutics by Countries, Type, Application and Manufacturers

8.1 South America Anti-Obesity Therapeutics Sales, Revenue and Market Share by Countries

8.1.1 South America Anti-Obesity Therapeutics Sales by Countries (2013-2018)

8.1.2 South America Anti-Obesity Therapeutics Revenue by Countries (2013-2018)

8.1.3 Brazil Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

8.1.4 Argentina Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

8.1.5 Colombia Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

8.2 South America Anti-Obesity Therapeutics Sales and Revenue (Value) by Manufacturers (2016-2017)

8.2.1 South America Anti-Obesity Therapeutics Sales by Manufacturers (2016-2017)

8.2.2 South America Anti-Obesity Therapeutics Revenue by Manufacturers (2016-2017)

8.3 South America Anti-Obesity Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

8.3.1 South America Anti-Obesity Therapeutics Sales and Sales Share by Type (2013-2018)

8.3.2 South America Anti-Obesity Therapeutics Revenue and Revenue Share by Type (2013-2018)

8.4 South America Anti-Obesity Therapeutics Sales, Revenue and Market Share by Application (2013-2018)

8.4.1 South America Anti-Obesity Therapeutics Sales and Sales Share by Application (2013-2018)

8.4.2 South America Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2013-2018)

9 Middle East and Africa Anti-Obesity Therapeutics by Countries, Type, Application and Manufacturers

9.1 Middle East and Africa Anti-Obesity Therapeutics Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Anti-Obesity Therapeutics Sales by Countries (2013-2018)

9.1.2 Middle East and Africa Anti-Obesity Therapeutics Revenue by Countries (2013-2018)

9.1.3 Saudi Arabia Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

9.1.4 UAE Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

9.1.5 Egypt Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

9.1.6 Nigeria Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

9.1.7 South Africa Anti-Obesity Therapeutics Sales and Growth Rate (2013-2018)

9.2 Middle East and Africa Anti-Obesity Therapeutics Sales and Revenue (Value) by Manufacturers (2016-2017)

9.2.1 Middle East and Africa Anti-Obesity Therapeutics Sales by Manufacturers (2016-2017)

9.2.2 Middle East and Africa Anti-Obesity Therapeutics Revenue by Manufacturers (2016-2017)

9.3 Middle East and Africa Anti-Obesity Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

9.3.1 Middle East and Africa Anti-Obesity Therapeutics Sales and Sales Share by Type (2013-2018)

9.3.1 Middle East and Africa Anti-Obesity Therapeutics Revenue and Revenue Share by Type (2013-2018)

9.4 Middle East and Africa Anti-Obesity Therapeutics Sales, Revenue and Market Share by Application (2013-2018)

9.4.1 Middle East and Africa Anti-Obesity Therapeutics Sales and Sales Share by Application (2013-2018)

9.4.2 Middle East and Africa Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2013-2018)

10 Global Anti-Obesity Therapeutics Market Segment by Type

10.1 Global Anti-Obesity Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Anti-Obesity Therapeutics Sales and Market Share by Type (2013-2018)

10.1.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Centrally Acting Anti-obesity Drugs Sales Growth and Price

10.2.1 Global Centrally Acting Anti-obesity Drugs Sales Growth (2013-2018)

10.2.2 Global Centrally Acting Anti-obesity Drugs Price (2013-2018)

10.3 Peripherally Acting Anti-obesity Drugs Sales Growth and Price

10.3.1 Global Peripherally Acting Anti-obesity Drugs Sales Growth (2013-2018)

10.3.2 Global Peripherally Acting Anti-obesity Drugs Price (2013-2018)

11 Global Anti-Obesity Therapeutics Market Segment by Application

11.1 Global Anti-Obesity Therapeutics Sales Market Share by Application (2013-2018)

11.2 Hospital Use Sales Growth (2013-2018)

11.3 Clinic Use Sales Growth (2013-2018)

11.4 Household Sales Growth (2013-2018)

11.5 Other Sales Growth (2013-2018)

12 Anti-Obesity Therapeutics Market Forecast (2018-2023)

12.1 Global Anti-Obesity Therapeutics Sales, Revenue and Growth Rate (2018-2023)

12.2 Anti-Obesity Therapeutics Market Forecast by Regions (2018-2023)

12.2.1 North America Anti-Obesity Therapeutics Market Forecast (2018-2023)

12.2.2 Europe Anti-Obesity Therapeutics Market Forecast (2018-2023)

12.2.3 Asia-Pacific Anti-Obesity Therapeutics Market Forecast (2018-2023)

12.2.4 South America Anti-Obesity Therapeutics Market Forecast (2018-2023)

12.2.5 Middle East and Africa Anti-Obesity Therapeutics Market Forecast (2018-2023)

12.3 Anti-Obesity Therapeutics Market Forecast by Type (2018-2023)

12.3.1 Global Anti-Obesity Therapeutics Sales Forecast by Type (2018-2023)

12.3.2 Global Anti-Obesity Therapeutics Market Share Forecast by Type (2018-2023)

12.4 Anti-Obesity Therapeutics Market Forecast by Application (2018-2023)

12.4.1 Global Anti-Obesity Therapeutics Sales Forecast by Application (2018-2023)

12.4.2 Global Anti-Obesity Therapeutics Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Anti-Obesity Therapeutics Picture

Table Product Specifications of Anti-Obesity Therapeutics

Figure Global Anti-Obesity Therapeutics CAGR (%), Y-o-Y Growth (&) and Ma

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery